News

Athera Biotechnologies, an atherosclerosis R&D company developing novel products for treatment and prevention of cardiovascular disease (CVD), and ALPCO, a company providing quality research immunoassays, have signed a

China Biologic Products (China Biologic) entered into a research and development agreement with the Institute of Blood Transfusion (IBT) on September 11, 2009, to strengthen the company’s research

ThromboGenics has completed the enrollment of the US phase III trial evaluating microplasmin for the non-surgical treatment of eye disease. The trial TG-MV-006 has completed enrollment of 326

Arch Chemicals has appointed three new members to its senior management team. The individuals are assuming the operational responsibilities that had previously been managed by the company’s former

EnWave has announced that it has dried three different antibodies in the company’s prototype freezeREV vial dehydration technology. Results from the study showed no detectable visual difference between

Eisai has announced that it has reached an agreement with Pfizer regarding the strategic alliance for the Alzheimer’s Disease treatment, Aricept (donepezil hydrochloride). Reportedly Eisai and Pfizer have

Galapagos has announced that its service division, BioFocus DPI, has initiated a drug discovery collaboration with Schering-Plough Research Institute (SPRI). As per the agreement, BioFocus DPI would perform

A phase III clinical trial involving more than 16,000 adult volunteers in Thailand has demonstrated that an investigational HIV vaccine regimen was safe and effective in preventing HIV

Cephalon has announced that the FDA has granted a priority review for its supplemental New Drug Application (sNDA) for NUVIGIL (armodafinil) tablets [C-IV], which was filed in June